Acumen Pharmaceuticals

Yahoo Finance • last year

Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures

Provides additional capital to support development of a subcutaneous formulation of ACU193 and general corporate purposes$30 million drawn down at loan closing CHARLOTTESVILLE, Va., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceutica... Full story

Yahoo Finance • last year

Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights

Initiation of a Phase 2 study, ALTITUDE-AD, to investigate ACU193 for the treatment of early Alzheimer’s disease expected in the first half of 2024, following positive FDA interaction in October 2023 Announced global collaboration and lic... Full story

Yahoo Finance • last year

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta... Full story

Yahoo Finance • last year

Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023

CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets... Full story

Yahoo Finance • last year

Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology

Yahoo Finance • last year

Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference

CHARLOTTESVILLE, Va., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the trea... Full story

Yahoo Finance • last year

Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease at the 16th Annual Clinical Trials on Alzheimer’s Disease

- Acumen presented data exploring target engagement modeling of ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody, to inform dose selection, plus further analyses of dose-related amyloid plaque reduction and c... Full story

Yahoo Finance • last year

Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD)

Expanded analyses from robust Phase 1 INTERCEPT-AD trial exploring novel target engagement (dose-related), amyloid plaque reduction, and ARIA levels observed with ACU193 administration to be included in a symposium on Friday, October 27 N... Full story

Yahoo Finance • last year

Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

CHARLOTTESVILLE, Va. and CARMEL, Ind., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta olig... Full story

Yahoo Finance • last year

Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference

CHARLOTTESVILLE, Va. and CARMEL, Ind., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta olig... Full story

Yahoo Finance • last year

12 Best NASDAQ Penny Stocks to Buy

In this article, we discuss 12 best NASDAQ penny stocks to buy. You can skip our detailed analysis of the stock market and returns of NASDAQ, and go directly to read 5 Best NASDAQ Penny Stocks to Buy. Since the start of 2023, the stock ma... Full story

Mentioned:

Yahoo Finance • last year

Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla

SEATTLE, June 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the appo... Full story

Mentioned:

ABBV

Yahoo Finance • 2 years ago

Acumen Pharmaceuticals to Present Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease During Featured Research Session at the Alzheimer’s Association International Conference (AAIC®) 2023

Topline results for ACU193, the first clinical stage amyloid beta oligomer (AβO)-directed antibody, to provide deeper insight into candidate’s therapeutic potential for the treatment of early Alzheimer’s diseasePhase 1 INTERCEPT-AD data in... Full story

Yahoo Finance • 2 years ago

Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights

Expect to report topline results from INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease, in the third quarter of 2023Cash, cash equivalents and marketable securities of $183.8 million as of March 3... Full story

Yahoo Finance • 2 years ago

Acumen Pharmaceuticals to Participate in 2023 Bank of America Healthcare Conference

CHARLOTTESVILLE, Va. and CARMEL, Ind., May 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligom... Full story

Yahoo Finance • 2 years ago

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023

CHARLOTTESVILLE, Va. and CARMEL, Ind., May 02, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic... Full story

Yahoo Finance • 2 years ago

Acumen Pharmaceuticals Presents in vitro Human Neuron Model for Evaluating Binding of Amyloid Beta Oligomers in Alzheimer’s Disease

Data describe induced pluripotent stem cell (iPSC)-derived excitatory neurons as a human model for assessing selectivity of drug binding to soluble amyloid beta oligomers in Alzheimer’s disease Results provide evidence that oligomer size m... Full story

Yahoo Finance • 2 years ago

Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights

INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease, completed enrollment in February 2023 Topline data expected in the third quarter of 2023 Cash, cash equivalents and marketable securities of $193... Full story

Yahoo Finance • 2 years ago

Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 22, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta olig... Full story

Yahoo Finance • 2 years ago

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 20, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical developing a novel therapeutic that targets toxic soluble amyloid beta oligomers fo... Full story